COLABORADOR

• MedSir (MedOPP098): Ensayo clı́nico de fase II de la actividad deRadio 223 en pacientes con cáncer de próstata metastásico resistente a lacastración (CPRCm) con progresión asintomá tica durante el tratamiento conacetato de abiraterona o enzalutamida y en función del estado mutacional delgen AR-V7 (2016)

• Astellas Pharma Global Development: Protocol 9785-CL-0335: A Multinational, Phase 3, Randomized, Double-blind, Placebo controlledEfficacy and Safety Study of Enzalutamide Plus AndrogenDeprivation Therapy (ADT) Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC) (2016)

• MK-3475-365-00: Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (2016) 

• MK-3475 Protocol 199: Phase II Trial of Pembrolizumab (MK-3475) in Subjects with mCRPC Previously Treated with Chemotherapy (2016) 

• 56021927PCR3003:_Estudio fase 3 aleatorizado, doble ciego y controlado con placebo de JNJ-56021927 en sujetos con cáncer de próstata localizado o localmente avanzado y de alto riesgo que estén recibiendo tratamiento con radioterapia primaria (2016)

• Bayer (Clinical Study Protocol BAY 88-8223/16298): A phase II randomized, double-blind, placebo-controlled trial of radium-223 dichloride versus placebo when administered to metastatic HER2 negative hormone receptor positive breast cancer subjects with bone metastases treated with hormonal treatment background therapy (2016)

• Nordic Nanovector ASA (LYMRIT-37-06)Estudio fase II del conjugado anticuerpo-radionúclido 177Lu-DOTA-HH1 (BetalutinTM) en pacientes con linfoma folicular recidivante CD37 positivo (2015)

• Bayer, Covance: Study 16507: A three arm randomized, open-label Phase II study of radium-223 dichloride 50 kBq/kg versus 80 kBq/kg, and versus 50 kBq/kg in an extended dosing schedule in subjects with castration resistant prostate cancer metastatic to the bone (2014)